Dolores Cahill, Molecular Biologist & Immunologist – Ireland
***By injecting messenger RNA if it has protein from the virus like the spike protein, this plus positive RNA can go into our cells. The spike protein from the virus is expressed in our cells and may be exposed to the immune system when those cells die and the body starts mounting an immune response including an antibody response.***
If people were vaccinated in December, then in 2-3 weeks the process would start. If in February, March or April, another coronavirus is circulating naturally in 2021, that would be like a challenge to the immune system of a vaccinated person with the natural coronavirus (like SARS) or even the common cold. What happened in the study, the animal models got very sick & some of them died. Last sentence of study – “However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.”
Watch & listen carefully from 4 Minutes on where she explains how a person’s body who has been vaccinated with mRNA genes reacts!
The name for this thing is antibody dependence response or cytokines storm or immunopriming or immuno superpriming. This is why there has been no vaccine licensed for decades for the coronavirus!
Could be one month to one to two years and then people get very sick and will die quickly. Many children given the SARS vaccine (Two children out of 35 children) died. What was concluded was that the disease was enhanced by the prior vaccines!
Background: Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease.
Design: Four candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or C57BL/6 mice were vaccinated IM on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology.
Results: All vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence.
Conclusions: These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.”
Purpose: Receiving influenza vaccination may increase the risk of other respiratory viruses, a phe- nomenon known as virus interference. Test-negative study designs are often utilized to calculate influ- enza vaccine effectiveness. The virus interference phenomenon goes against the basic assumption of the test-negative vaccine effectiveness study that vaccination does not change the risk of infection with other respiratory illness, thus potentially biasing vaccine effectiveness results in the positive direction. This study aimed to investigate virus interference by comparing respiratory virus status among Department of Defense personnel based on their influenza vaccination status. Furthermore, individual respiratory viruses and their association with influenza vaccination were examined.
Results: We compared vaccination status of 2880 people with non-influenza respiratory viruses to 3240 people with pan-negative results. Comparing vaccinated to non-vaccinated patients, the adjusted odds ratio for non-flu viruses was 0.97 (95% confidence interval (CI): 0.86, 1.09; p = 0.60). Additionally, the vac- cination status of 3349 cases of influenza were compared to three different control groups: all controls (N = 6120), non-influenza positive controls (N = 2880), and pan-negative controls (N = 3240). The adjusted ORs for the comparisons among the three control groups did not vary much (range: 0.46–0.51). Conclusions: Receipt of influenza vaccination was not associated with virus interference among our population. Examining virus interference by specific respiratory viruses showed mixed results. Vaccine derived virus interference was significantly associated with coronavirus and human metapneumovirus; however, significant protection with vaccination was associated not only with most influenza viruses, but also parainfluenza, RSV, and non-influenza virus coinfections.
IT STARTS: SEATTLE FIRE WILL GO DOOR TO DOOR TO “ADULT FAMILY” HOMES ADMINISTER COVID-19 VACCINES
“The city of Seattle was approved late last week as a distributor of COVID-19 vaccines, Mayor Jenny Durkan announced. ‘The City’ refers to anyone employed and currently accepting a paycheck from the city government of Seattle. Durkan framed the new push as the first in what will eventually be a major city effort to distribute the vaccine from sites spread throughout the city.
‘It will really have to be an all-hands-on-deck approach,’ she said according to a report by EMS1 EMS1. The mayor stressed that to reach the 70% vaccination rate of its adult population, King County will have to vaccinate 1.3 million people, giving out 2.6 million shots. ‘It is an undertaking that our country has never done before, not on this scale.’”
“In order to accomplish this goal, the country will begin a ‘trial’ of keeping vaccine sites open 24 hours per day, 7 days a week.
‘Our target is by September to have offered all the adult population a first dose,’ Raab told Sky News.
Britain has chosen to stretch out the time between vaccine doses from 21 days to up to 12 weeks. This means more people will get at least one dose of this vaccine more quickly. The U.K. has also approved three vaccines, one by Pfizer-BioNTech, Oxford-AstraZeneca, and Moderna. The first two are already being used, while the Moderna doses are not expected until spring.“
Note from Expat Gal – Sorry everyone for the delay in getting this out. I literally wrote most of this post (excluding the last link for Seattle) 1 1/2 weeks ago & then burnt out on how evil this vaccine & its effects are & had to take a break coupled with the Z3 News website being inaccessible for 3 days. ?
WARN loudly & frequently….everyone you know! Do not take this vaccine! It will harm your body in countless ways & I believe your free will & soul as well. Reach people with this information any way you can!
Author: Expat Gal
Expat Gal has been blessed to have known God as long as she can remember. She was raised Catholic and was baptized, made her First Communion and was confirmed in the Catholic faith. At 21, she left the Catholic faith to become a non-denominational Christian as she began to question some Catholic doctrine. One of her life’s highlights was her family’s lake baptism in 2013. In late March 2015, she received a strong Word from the Lord that your “family is no longer safe here” so she and her family permanently relocated outside the U.S. Her goal is to serve the Lord in any capacity He calls her to serve in.
© 2021, Z3 News. The first 200 words of Z3 News articles may be shared online in exchange for a clickable link to our site. Please include the author name and do not make any changes to text or titles. No image files from our site may be shared because we don’t own them. For permission to use our content in other formats, please contact us.